Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia

James S. Brown Jr*
Department of Psychiatry, VCU School of Medicine, Richmond, VA
*To whom correspondence should be addressed; PO Box 622, Midlothian, VA 23113, US; tel: 804-564-9454, e-mail: jbrown2185@aol.com

For at least a century, a debate has continued as to whether cancer risk is reduced in schizophrenia. Genetic studies have also suggested the 2 conditions may share protein transcriptional pathways. The author predicted that if the pathophysiology of schizophrenia confers protection from cancer, then the immunology of schizophrenia should reflect a state of tumor suppression, i.e., the opposite of tumor escape. To examine this possibility, the author performed a literature search for measurements of cytokines in drug-naïve first episode subjects with schizophrenia for comparison with cytokine expression in tumor escape vs tumor suppression. The comparison showed that instead of either tumor suppression or escape, schizophrenia appears to be in a state of tumor equilibrium. Based on this finding, the author hypothesized that the clinical presentation of schizophrenia may involve cell transformation similar to an early stage of cancer initiation or an attenuated tumorigenesis. While this condition could reflect the presence of an actual tumor such as an ovarian teratoma causing anti-NMDA receptor encephalitis, it would only explain a small percentage of cases. To find a more likely tumor model, the author then compared the cytokine profile of schizophrenia to individual cancers and found the best match was melanoma. To demonstrate the viability of the theory, the author compared the hallmarks, emerging hallmarks, and enabling characteristics of melanoma to schizophrenia and found that many findings in schizophrenia are understood if schizophrenia is a condition of attenuated tumorigenesis.

Key words: schizophrenia/cancer/immunology/tumor/melanoma

Introduction

For over 100 years it has been debated whether individuals with schizophrenia have reduced risk of cancer, and many early studies did find schizophrenia seemed to protect from cancer in general. For at least a century, a debate has continued as to whether cancer risk is reduced in schizophrenia. Genetic studies have also suggested the 2 conditions may share protein transcriptional pathways. The author predicted that if the pathophysiology of schizophrenia confers protection from cancer, then the immunology of schizophrenia should reflect a state of tumor suppression, i.e., the opposite of tumor escape. To examine this possibility, the author performed a literature search for measurements of cytokines in drug-naïve first episode subjects with schizophrenia for comparison with cytokine expression in tumor escape vs tumor suppression. The comparison showed that instead of either tumor suppression or escape, schizophrenia appears to be in a state of tumor equilibrium. Based on this finding, the author hypothesized that the clinical presentation of schizophrenia may involve cell transformation similar to an early stage of cancer initiation or an attenuated tumorigenesis. While this condition could reflect the presence of an actual tumor such as an ovarian teratoma causing anti-NMDA receptor encephalitis, it would only explain a small percentage of cases. To find a more likely tumor model, the author then compared the cytokine profile of schizophrenia to individual cancers and found the best match was melanoma. To demonstrate the viability of the theory, the author compared the hallmarks, emerging hallmarks, and enabling characteristics of melanoma to schizophrenia and found that many findings in schizophrenia are understood if schizophrenia is a condition of attenuated tumorigenesis.

Key words: schizophrenia/cancer/immunology/tumor/melanoma

Introduction

For over 100 years it has been debated whether individuals with schizophrenia have reduced risk of cancer, and
microenvironments are low in oxygen and pH and drain to lymph nodes where tumor-associated microenviron-
ments can be established and in later stages can be observed systematically.

Changes in cytokines such as the interleukins are only one aspect of the complex process of immunoediting which is an area of intense research interest due to the recent resurgence of immunological treatments of cancer. The numerous mechanisms of tumor or immune escape have been reviewed in detail in several excellent sources and can be generally categorized as types of altered antigen presentation, defects in innate immunity such as abnormal NK cells, and accumulation of so-called alternatively activated polarized M2 macrophages; defective T-cell responses including T-cell exhaustion or anergy, and various other mechanisms that include cytokine changes, changes in metabolism that alter apoptosis, and effector immune cell responses. Immunoediting in brain cancer occurs in a similar fashion.

Interferons and interleukins are cytokines that are proteins like hormones in that they are cell-to-cell messen-
gers but cytokines act in the “microenvironment,” usually target fewer cells than hormones, and are involved in the immune response. Interferon-γ, one of several interferons originally named for their regulation of the immune response in response to viral infections, also recruits phagocytic macrophages and promotes the differentiation of CD4+ T cells to the Th1 subset while inhibiting the development of Th2 and Th17 cells. Interleukins are cytokines originally believed to originate from and act on leukocytes (thus the name, inter-leuken) although the term has become more generic with the discovery of other sources and actions.

The author predicted that if schizophrenia reduces the risk of cancer, a significant difference might be observed between the cytokine immunology of tumor escape and that of schizophrenia. More specifically, the author theo-
rized that if schizophrenia reduced cancer risk, then the comparison of cytokine expression would demonstrate schizophrenia was in state of tumor suppression, i.e., the opposite of tumor escape. However, as the discussion below shows, this prediction was wrong in predicting “suppression” as it became apparent that the secretion profile of cytokines in medication-naïve first-episode subjects with schizophrenia appears the same as tumor equilibrium as defined by the cytokine expression profiles suggested by Teng et al and Lippitz. Schizophrenia from the perspective of cytokine expression in the absence of a tumor cannot be differentiated from an initiation phase of cancer, and on comparison to specific tumors, has similarities to the cytokine expression of melanoma.

Methodology

A large review of biomarkers in schizophrenia published in 2010 found that relatively few studies performed measurements in medication-naïve patients. This is important because even though immunological dysfunction was observed in schizophrenia decades before the existence of antipsychotic medications, the immunological side effects of these medications have been known for some time. For the current study, the author searched on Pubmed for all studies of cytokines in psychotic subjects published after 2010 (to add to those studies available in the above-mentioned 2010 biomarkers review). To rigorously control for medication effects on cytokine expression only in schizophrenia, studies were then selected that only examined first episode, drug-naïve subjects with only the diagnosis of schizophrenia. This excluded studies of mixed groups of subjects with diverse diagnoses other than schizophrenia like bipolar disorder, schizoaffective disorder or other psychotic disorders; studies that included previously treated subjects who were not taking medications for some period of time, usually weeks, before the measurements or in which subjects had been medicated for very brief periods of time shortly before measurements were obtained; studies in which the medica-
tion state or procedures were not clearly described, and reviews and meta-analyses that included medicated patients. This excluded nearly 100 studies published since 2010 of cytokine levels in schizophrenia and left only 10 studies for comparison, 9 of which were published since 2010. The 10 studies described above provided measurements of IFN-γ, TNF-α and 11 interleukins (to include receptor antagonist ILRA) including IL1β, IL1RA, IL2, IL6, IL8, IL10, IL12, IL15, IL17, IL18, and IL23. Information regarding the immunological state of the tumor microenvironment during immune escape and equilibrium to compare to these cytokines was obtained from the extensive monographic literature on the subject of tumor immunology, as well as searches of Pubmed.

Findings

Table 1 illustrates the cytokine changes in schizophrenia including IFN-γ, interleukin and TNF-α compared to their expression in the tumor microenvironment during tumor escape, tumor equilibrium according to Teng et al, a cancer “profile” of cytokines suggested by Lippitz as an indicator of simultaneous immunostimulation and immuno-
suppression, and melanoma. Teng et al described the essential components of tumor equilibrium as IFN-γ, IL-12 and CD4+ and CD8+ T cells. The current study did not examine CD4+ and CD8+ T cells but a meta-
analysis of T-cell subsets found that both subsets are ele-

tivated in drug-naïve, first-episode schizophrenia which parallels the increases observed in IFN-γ and IL-12 in tumor equilibrium shown on table 1. Table 1 also includes transforming growth factor β (TGF-β) and macrophage migration inhibitory factor (MIF) as part of a proposed cancer profile by Lippitz. Although the author found no studies of TGF-β and MIF in schizophrenia that met
the stringent criteria described above, both biomarkers have been studied in medicated subjects which will be discussed below.

With the exception of TGF-β and MIF which were excluded from the schizophrenia studies on table 1, the table shows an agreement between IFN-γ and interleukin expression in schizophrenia with the tumor equilibrium profile of Teng et al. and the balanced immunosuppression and immunostimulation of cancer proposed by Lippitz. Combined, these profiles include the levels of IFN-γ, IL6, IL8, IL10, IL12, and IL18. Interleukin 10 has, according to Gopal et al. an “enigmatic” function in cancer as this interleukin is both immunosuppressive and immunostimulating, and studies have found both increased and decreased levels in both tumor escape and schizophrenia as shown on table 1. TNFα and the remaining interleukins except for IL2 on table 1 agree with a state of tumor escape, ie, similar expressions in schizophrenia with tumor escape are seen for IL1β, IL1RA, IL15, and IL17. IL23 is considered part of IL12.

As mentioned above, TGF-β and MIF were excluded from the schizophrenia studies in table 1 although both have been studied in medicated subjects with psychotic illness, and both have roles in tumor immunology. Numerous studies including one meta-analysis have found TGF-β1 elevated in schizophrenia although other studies have found no difference. TGF-β is clearly elevated in cancer and although in the early stages of cancer it can act as a tumor suppressor while becoming a promoter as cancer progresses. The activity of TGF-β in medicated subjects with schizophrenia does agree with the cancer profile of Lippitz. MIF was identified in a large biomarker survey of schizophrenia as associated with decreased risk of schizophrenia, and it does contribute significantly to tumor escape (references in table 1) placing it tentatively in the same category as IL2.

The melanoma cytokine profile as shown on table 1 does however differ from schizophrenia as melanoma has decreased interferon-γ, which is consistent with tumor escape rather than equilibrium; but melanoma happens to have increased vascular endothelial growth factor (VEGF) compared to reduced VEGF in first episode, drug-naïve schizophrenia. VEGF is a potent angiogenic factor closely involved in the angiogenesis hallmark of cancer due to its important role in tumor progression and its tumor-promoting actions are suppressed by IFN-γ. Under normal conditions, IL-12 increases INF-γ which would sustain tumor equilibrium, but in

### Table 1. Cytokine Changes in Drug-Naïve First Episode Schizophrenia Compared to the Tumor Microenvironment

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Schizophrenia</th>
<th>Tumor Escape</th>
<th>Tumor Equilibrium</th>
<th>Cancer Profile</th>
<th>Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>INF-γ</td>
<td>↑ ref.42</td>
<td></td>
<td>ref.3,43,44</td>
<td></td>
<td>↑ ref.36,37</td>
</tr>
<tr>
<td>IL1β</td>
<td>↑ ref.45–47</td>
<td>↑ ref.48–50</td>
<td>ref.3,53,54</td>
<td></td>
<td>↑ ref.31</td>
</tr>
<tr>
<td>IL1RA</td>
<td>↑ ref.32</td>
<td>↑ ref.49,52</td>
<td>ref.43,56</td>
<td></td>
<td>↑ ref.35</td>
</tr>
<tr>
<td>IL2</td>
<td>↑ ref.37</td>
<td>↑ ref.19,44</td>
<td>ref.4,54</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL6</td>
<td>↑ ref.2,45,46</td>
<td>↑ ref.19,44</td>
<td>ref.3,13,19,23,61</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL8</td>
<td>↑ ref.43,46</td>
<td>↑ ref.21,43</td>
<td>ref.23,43</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL10</td>
<td>↑ ref.43</td>
<td>↑ ref.19,47</td>
<td>ref.19,47</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL12</td>
<td>↑ ref.2,45</td>
<td>↑ ref.19,47</td>
<td>ref.19,47</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL15</td>
<td>↑ ref.32</td>
<td>↑ ref.19,47</td>
<td>ref.19,47</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL17</td>
<td>↑ ref.38</td>
<td>↑ ref.19,47</td>
<td>ref.19,47</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL18</td>
<td>↑ ref.38</td>
<td>↑ ref.19,47</td>
<td>ref.19,47</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>IL23(=IL 12)</td>
<td>↑ ref.39</td>
<td>↑ ref.19,47</td>
<td>ref.19,47</td>
<td></td>
<td>↑ ref.37</td>
</tr>
<tr>
<td>TNF-α</td>
<td>↑ ref.47</td>
<td>↑ ref.34</td>
<td>ref.19,23</td>
<td></td>
<td>↑ ref.71</td>
</tr>
<tr>
<td>TGF-β</td>
<td>N/A</td>
<td>↑ ref.19,72</td>
<td>ref.19,72</td>
<td></td>
<td>↑ ref.73</td>
</tr>
<tr>
<td>MIF</td>
<td>N/A</td>
<td>↑ ref.19,72</td>
<td>ref.19,72</td>
<td></td>
<td>↑ ref.73</td>
</tr>
</tbody>
</table>

**Note:** MIF, migration inhibitory factor; IL, Interleukin; TGF-β, transforming growth factor β; TNF-α, Tumor Necrosis Factor-α.
melanoma IFN-γ is not increased which would allow VEGF to promote tumor angiogenesis. This shows that an important difference between the cytokine profiles of schizophrenia and melanoma is that the tumor-promoting effects of VEGF are suppressed in the former and released in the latter. Other immunological similarities and differences between schizophrenia and melanoma are borne out by comparing other cytokines on table 1 between the 2 conditions. Like schizophrenia, melanoma has elevated IL1β, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, and IL-23; but unlike schizophrenia has decreases of IL-1RA (in uveal melanoma) and IL-2; and increased or decreased TNF-α.

Discussion

The numerous studies of the relationship between schizophrenia and cancer have asked if cancer risk is altered from baseline. While this study set out to address that question, the findings do not equate to any of the epidemiological relations discussed above such as “increased” or “decreased” risk because the immune system in schizophrenia is neither “quiet” as would be expected if cancer risk was unchanged nor is it polarized toward reducing or increasing risk from cancer. Schizophrenia cytokine expression is more like tumor equilibrium than to either tumor suppression or escape. The initial impression is that schizophrenia has some similarity to cancer itself although without a growing tumor, ie, in a state of tumor equilibrium. This is not the first study of schizophrenia to observe that, unlike many studies claim, schizophrenia is not a pure state of inflammation but rather one with both inflammatory and anti-inflammatory characteristics.74

Besides tumor equilibrium, there are 2 other circumstances in which similar findings may appear, namely, chronic infection and the maternal immune tolerance of the semi-allogenic fetus.75,76 Although substantial literature supports maternal infection as a risk factor for schizophrenia, chronic infection of the type necessary to sustain this cytokine profile since birth has not been linked to schizophrenia. While there are many theories that suggest prenatal programming from maternal infection initiates a persistent inflammatory state that results in schizophrenia, the immunology as described above does not support a persistent and purely inflammatory state.

The data instead lead to the hypothesis that the clinical presentation of schizophrenia might involve cell transformation similar to an early stage of cancer initiation in equilibrium.

If so, there are at least 2 possible explanations of how a tumor or tumor-like condition could cause schizophrenia. The first is that some cancers cause psychosis such as ovarian (and other) tumors that cause autoimmune anti-N-methyl-D-aspartate (NMDA)-receptor encephalitis (NMDR-E). NMDR-E, first described in 1997, results from IgG antibodies against the NMDA receptor NR1 subunit. The condition often begins with a viral-like syndrome followed by treatment-resistant psychotic symptoms accompanied by movement disorders, seizures, and catatonia.77

Although only a small percentage of cases of psychosis are anti-NMDA receptor antibody positive79 and there is no altered risk of ovarian cancer in schizophrenia,1 clinicians should consider this diagnosis in treatment-resistant schizophrenia accompanied by neurological abnormalities. Most cases of NMDR-E are associated with germ-cell tumors, especially ovarian teratomas, although non-germ cell tumors can be involved; are more common in women than men, and can result in coma and death if the tumor is not removed.77 When no tumor is found, microscopic, undetectable germ cell tumors are suspected.77 The percentage of new onset psychoses without encephalitis caused by NMDR-E is unknown although such cases are reported.79

Cytokine studies in teratomas are too few to adequately compare to table 1 but there are case reports of increased IL-6 in ovarian and mediastinal teratomas,80,81 increased IL-8 in mediastinal teratoma,82 increased IL-2, 6, and 10 in experimental murine testicular teratoma,83 reduced IL12p40 in embryonic stem cell-extract-treated monocytic-derived dendritic cells83 which may contribute to teratoma formation; increased MIIF in bone marrow-derived macrophages after embryonic stem cell transplantation,84 increased TNF-α in embryonic stem cell-exposed macrophages85 and increased TGF-β in a teratocarcinoma cell line.86 This limited information places teratomas more in line with the Cancer Profile than Equilibrium on table 1, mostly due to reduced IL-12.

The comparison of cytokine profiles of specific cancers to schizophrenia described above failed to find an exact match, but did reveal melanoma as a close approximation. This finding is notable as melanocytes and neurons share not only embryological origins in neural crest cells but also many signaling molecules.87 The antipsychotic medication pimozide has even been successfully used to treat melanoma,88 and the inhibitory effect on growth appears related to competitive dopamine (DA) binding89 although this may be related to low affinity binding to melanin.90 Interestingly, melanoma and Parkinson’s Disease (PD) are mutual risk factors,88,89 PD is a risk factor for schizophrenia,90 and PD is known, like schizophrenia, for a reduced risk of cancer except for breast cancer and melanoma.91 The relationship of DA to melanin are outside the scope of this study but supports melanoma as a good candidate tumor to compare to schizophrenia.

This leads to the question as to how close an approximation is melanoma of schizophrenia when other characteristics of cancer are compared. This can be determined by using Hanahan and Weinberg’s 6 hallmarks of cancer proposed in 200093 and expanded to 8 hallmarks and 2 “enabling characteristics” in 2011.94 The first 6 hallmarks were “sustaining proliferative signaling, evading growth
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis” (p. 646). The 2 emerging hallmarks were “reprogramming of energy metabolism and evading immune destruction” (p. 646), and the 2 “enabling characteristics” were “tumor-promoting inflammation” and “genome instability and mutation.” Having already discussed immune destruction and tumor-promoting inflammation above, the remaining discussion examines how molecular characteristics of schizophrenia are either similar to or are mirror images of the remaining cancer hallmarks and characteristics.

**Sustaining Proliferative Signaling**

Sustaining proliferative signaling is described as “arguably the most fundamental trait of cancer cells”94 (p. 646). Weinberg’s95 states “…cancer is really a disease of aberrant signal processing.” (p. 176). Aberrant signal processing is also fundamental to schizophrenia as the DA hypothesis of schizophrenia holds, in general, that increased DA signaling in the striatum causes positive symptoms, and decreased DA in cortical regions causes negative and cognitive symptoms. This was shown in a recent meta-analysis of the striatal DA hypothesis of schizophrenia that concluded “The locus of the largest dopaminergic abnormality in schizophrenia is presynaptic-affecting DA synthesis capacity, baseline synaptic DA levels and DA release.”97 (p. 776).

The most important endogenous proliferative signaling in most cancers including melanoma is the Erk cascade: growth factors— receptor tyrosine kinases—growth factor receptor binder 2 (Grb2)—Son of Sevenless—GTP bound Ras proteins—Raf—mitogen activated protein kinase kinases (ME2K or MEK)—Erk.95 An activating mutation of B-raf protein, eg, is involved in about 50% of melanomas, and this activation leads to phosphorylation of at least 60 proteins and loss of phosphorylation in about 30 proteins, all mediated by Erk95 (p. 192). Referring to the DA hypothesis, it is tempting to suggest the dopaminergic state of the striatum in schizophrenia results from increased Erk expression but on the contrary the evidence shows hyperactive striatal DA is actually the proliferative signal.

D2 DA receptor stimulation stimulates mitogenesis so that increased D2 signaling increases Erk98,99 and if increased Erk is a proliferative signal, then hyperactive DA in schizophrenia should be considered a proliferative signal. In glioblastoma, eg, D2 DA is a mitogenic signal acting through Erk signaling.100 Since a tumor is not present in the striatum in schizophrenia, the D2 signal is either insufficient or blocked from performing similar mitogenic signaling as the Erk pathway appears normal in the hippocampus101 and diminished in the frontal cortex of schizophrenia.102 However, the fact that the Erk pathway is closely involved in the regulation of VEGF and is involved in the control of apoptosis through the regulatory gene BCL-2103 which is also involved in schizophrenia,104 is further evidence of the involvement of proliferative signaling in schizophrenia.

There are other paths of proliferative signaling in cancer that could be related to schizophrenia such as the P13 kinase pathway, but one other path will be briefly mentioned because it involves glutamate which forms the basis of an additional schizophrenia theory. The glutamate hypothesis of schizophrenia holds that hypofunction of the glutamatergic NMDA receptor causes striatal DA hyperactivity and cortical DA hypoactivity.105 The metabotropic glutamate receptor 1 encoded by the GRM1 gene was recently found to have oncogenic properties in melanoma, and mutations of this gene also appear involved in schizophrenia.106 Similar findings in melanoma have been made for increased expression of mGlur5 and activating mutations in GRM3.107 Both mGlur5 and GRM3 are implicated in schizophrenia, but overall it appears that melanoma is associated with activated glutamate receptors and schizophrenia with deactivated glutamate receptors. Understanding how and why schizophrenia and melanoma have mirror image defects in these receptor functions will require additional research but is an example of the overlap of molecular pathways in the 2 conditions.

**Evading Growth Suppressors**

There are 2 major growth suppressors called tumor suppressor genes in cancer biology, one encodes the RB (retinoblastoma-associated) protein (pRb) and the other the TP53 protein.94 Mutations of both have been found in melanoma.108,109 Both pathways are complex, and reviews can be found in Weinberg’s monograph.95 Both have been studied in schizophrenia but only one, pRb, will be discussed in this section. TP53 is discussed in the following section.

In the case of pRb, phosphorylation controls the protein’s ability to block the cell cycle, and hyper-phosphorylation inactivates the protein’s gatekeeping control of the cell cycle and allows cells to proliferate. Hypophosphorylation, on the other hand, halts proliferation and facilitates differentiation. Mitogenic signals that hyper-phosphorylate can lead to deregulated proliferation and blocked differentiation which can accompany tumor progression. The cell cycle in schizophrenia does indeed appear altered and is accelerated compared to normal.112 Another study of schizophrenia reported increased phosphorylated pRb in the white matter underlying the anterior cingulate gyrus. This was described as diverting the oligodendrocytes that form the white matter from their differentiated state thus possibly causing the demyelination abnormalities in schizophrenia.113 In comparison to melanoma, dedifferentiation is an ominous sign,114 and finding a similar process in oligodendrocytes in schizophrenia is suggestive of a cancer-like state.
Resisting Cell Death

Resistance to cell death in cancer occurs mostly by blocking apoptosis which is accomplished through more than one mechanism, the most important ones being the loss of p53 function and/or inactivation of autophagy. Both mechanisms are active in melanoma. Apoptosis has been of interest in schizophrenia for some time although there has been debate whether it is increased or decreased. Some of the variation in findings appears related to the specific brain region being examined and/or the effect of antipsychotic medications which are known to influence apoptosis.

The p53 gene has indeed been identified as a candidate susceptibility gene for schizophrenia, and some of the gene’s role in schizophrenia may occur through pathways involving dysbindin and white matter integrity. The most important findings for the current study is of altered apoptotic markers in cultured fibroblasts from schizophrenia which indicate that schizophrenia has increased susceptibility to apoptosis, i.e., the opposite of cancer. One study found blocked autophagy in the hippocampus of schizophrenia although this was interpreted as indicating increased apoptosis in an alternate pathway.

How changes of apoptotic or anti-apoptotic signals are interpreted can seem paradoxical. For example, in PD, increased anti-apoptotic signals are interpreted as a compensation for increased neuronal apoptosis. In other words, the anti-apoptotic signals result from but do not cause the disease. In contrast, the increased apoptotic signals in schizophrenia have been implicated as a primary cause of schizophrenia by causing a neurodegenerative process similar to aging, and this is certainly possible because hyperactive p53 that markedly enhances apoptosis is associated with premature aging and resistance to cancer (p.343). But the author suggests that an alternate explanation of increased apoptotic signals in schizophrenia is that the signals are the result not of the cause of abnormal neurons, i.e., apoptotic mechanisms are attempting to remove abnormal neurons that are altered by neoplastic influences. This process, best described as an “attenuated tumorigensis” would be a secondary not primary cause of neurodegeneration.

Enabling Replicative Immortality

The widely accepted mechanism that cancer cells use to achieve replicative immortality is blocking telomere shortening. Telomeres protect the ends of chromosomes and are progressively shortened in cell propagation to where loss of chromosome protection causes end-to-end fusions that ultimately lead to cell death. Proliferation-associated abnormalities such as oncogenic signaling can trigger telomere shortening and result in attenuated tumorigenesis before any tumor growth occurs. Most tumors, including melanoma, block telomere shortening often through increased telomerase activity, the polymerase that lengthens telomeres by adding telomeric DNA. Shortened telomere lengths have been found in schizophrenia and shortened telomeres are positively associated with severity of symptoms. This is the opposite of what is found in cancer, so in the author’s tumor model, decreased telomere length in schizophrenia occurs in response to proliferative signaling before tumor growth occurs which is another form of attenuated tumorigenesis.

Inducing Angiogenesis

This hallmark was briefly discussed above in regard to VEGF which is the primary signaling factor for both normal and pathological blood vessel growth. In addition to what was discussed above, abnormal vascular architecture can develop early in tumor development and is noted for “precocious capillary sprouting, convoluted and excessive vessel branching, distorted and enlarged vessels, erratic blood flow, microhemorrhaging, leakiness, and abnormal levels of endothelial cell proliferation and apoptosis.” p. 653. Many of these same abnormalities are reported in several reports of vascular abnormalities in schizophrenia.

Activating Invasion and Metastasis

Schizophrenia is not associated with an invading, metastatic tumor. To the limited extent to which schizophrenia literature can examined for a connection to tumor invasion, the following can be stated. Tumor invasion depends on a complex alteration of the surrounding extracellular matrix. Altered adhesion molecules such as N-cadherin are usually upregulated in tumors including melanomas so that cell attachment during invasion can occur. In schizophrenia, the susceptibility gene disrupted-in-schizophrenia 1 (DISC1) regulates cell-matrix adhesion, and DISC1 overexpression enhances N-cadherin and cell-cell adhesion. To date schizophrenia has not been shown to involve an invading tumor in e.g., the striatum but the activity of DISC1 in schizophrenia would appear to allow it.

Genome Instability and Mutation

Genome instability and mutation is an enabling characteristic of cancer, and some of the abnormalities discussed above occur as a result of mutations. The number of mutations associated with cancer is quite large and for the purposes of this discussion it is sufficient to quote the authors who reported a decreased risk of melanoma in schizophrenia in Sweden who “found that more than 140 schizophrenia-associated genes were mutated in cancer.” p. 532.

Reprogramming of Energy Metabolism

The final emerging hallmark of cancer is the reprogramming of energy metabolism which might be the most...
interesting and controversial aspect of cancer biology because the subject involves “aerobic glycolysis” or the so-called Warburg effect. Weinberg describes this characteristic of cancer cells as “bizarre” p55 since cancer cells inefficiently metabolize glucose to lactate by using aerobic glycolysis when they have sufficient oxygen to use the more efficient mechanism of oxidative phosphorylation. Aerobic glycolysis explains the increased secretion of lactate from tumors. There are several reports of impaired glycolysis in schizophrenia including increased levels of lactate in first onset antipsychotic-naïve subjects. Increased cerebrospinal fluid lactate in schizophrenia has also been attributed to anaerobic glucose metabolism in schizophrenia and bipolar subjects.

Conclusion

Based on the discussion above, schizophrenia can be understood within the framework of 2 different tumor models although one, the model using NMDR-E, may only explain a small percentage of cases. The more likely tumor model is that schizophrenia is a condition of attenuated tumorigenesis. The author thinks of this as a balance between the emergence of a tumor and suppression of tumorigenic influences. Novel features of this model are: (1) schizophrenia is a suppressed tumor state with similarities to melanoma; (2) DA is the proliferative but blocked signal; (3) schizophrenia would present as a tumor except that certain hallmarks of cancer are oppositely expressed in schizophrenia; and (4) some characteristics of schizophrenia like apoptosis are the results of attenuated tumorigenesis. Finally, if this theory holds up to scrutiny, the root cause of abnormal dopaminergic signaling in schizophrenia should be sought from a tumorigenic standpoint. Consideration should also be given to clinical treatment of schizophrenia based on the principles of oncology to include treatments aimed at normalizing the abnormal immune responses described above.

Acknowledgment

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

References


Reale M, Patruno A, De Lutiis MA, et al. Dysregulation of
Hayes LN, Severance EG, Leek JT, et al. Inflammatory
tissue and peripheral blood of oral squamous cell carcinoma.
Baruah S. Negative regulation of natural killer cell in tumor
Dutta A, Banerjee A, Saikia N, Phookan J, Baruah MN,
Nagarkatti-Gude N, Bronkhorst IH, van Duinen SG, Luyten
Hirbod-Mobarakeh A, Amirzargar AA, Nikbin B, Nicknam
Gr-1+ myeloid cells antagonize senescence in cancer.
sychotic treatment.
in first-episode schizophrenia patients before and after antip
dewitte L, Tomasik J, Schwarz E, et al. Cytokine alterations
leukin-1beta.
flammation via caspase-1 processing and secretion of inter
inflammasome in human melanoma cells mediating autoin
impairs NK cell development and function.
strongly reduce expression of MITF-M and melanocyte dif
1alpha and 1beta secreted by some melanoma cell lines
Int J Cancer
γ by suppression of tumor-associated mac
Oncol Res
Cancer Immunotherapy: Immune
Serafini P, Bronte V. In: Gabrilovich DI, Hurwitz AA,
May KFJ, Jinushi M, Dranoff G. Chapter 8. In: Prendergast
Ding M, Song X, Zhao J, et al. Activation of Th17
Sun T, Yang Y, Luo X, et al. Inhibition of tumor angiogen
Schizophr Bull
J Biol Chem
Neuroendocrinology
Cancer Immunol Res
92.
94.
95.


